ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 648

Klinefelter’s Syndrome (47,XXY) Among Men with Sjögren’s Syndrome

Valerie M Harris1, Joshua Cavett2, Biji Kurien3, Ke Liu4, Kristi A. Koelsch5, Lida Radfar6, David M. Lewis7, Donald U. Stone8, Shibo Li9, Barbara Segal10, Daniel J Wallace11, Michael H. Weisman12, Jennifer A. Kelly13, Marta Alarcon-Riquelme14, Bernado Pons-Estel15, Roland Jonsson16, Xianglan Lu9, Jacques Gottenberg17, Juan-Manuel Anaya18, Deborah S. Cunninghame-Graham19, Edward C. Keystone20, Andrew J.W. Huang21, Michael T. Brennan22, Pamela Hughes23, G Illei24, Corinne Miceli25, VP Bykerk26, Gideon Hirschfield27, Gang Xie28, Wan-Fai Ng29, Gunnel Nordmark30, Per Eriksson31, Roald Omdal32, Nelson L. Rhodus33, Maureen Rischmueller34, Michael D. Rohrer35, Marie Wahren-Herlenius36, Torsten Witte37, Xavier Mariette38, Christopher Lessard39, John B. Harley40, Kathy L. Sivils39 and Robert Hal Scofield41, 1Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 43333 Burnet Ave., University of Cincinnati & Cincinnati Childre, Cincinnati, OH, 5Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, 6Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, 7College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 8King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, 9Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 10Rheumatology, Univ of Minnesota, Minneapolis, MN, 11Cedars-Sinai Medical Center, West Hollywood, CA, 12Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 13Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 14Arthritis & Clinical Immunology, Oklahoma Medical REsearch Foundtion, Oklahoma City, OK, 15Hospital Provincial de Rosario, Rosario, Argentina, 16Broegelmann research laboratory, Bergen, Norway, 17Hautepierre, Strasbourg, France, 18Cell Biol and Immunogenetics, CIB-Rosario University, Medellin, Colombia, 19Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, 20Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 21Department of Ophthalmology and Visual Sciences, Washington University, St Louis, MO, 22Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, 23Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, 24Sjögren's Clinic, NIDCR/NIH, Bethesda, MD, 25Rheumatology, PARIS, France, 26University of Toronto, Toronto, ON, Canada, 27Centre for Liver Research, Institute of Biomedical Research, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 28Mount Sinai Hospital, Toronto, ON, Canada, 29Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 30Medical Sciences, Uppsala University, Uppsala, Sweden, 31University Hospital, Rheumatology clinic, Linköping, Sweden, 32Department of internal medicine, Clinical Immunology unit, Stavanger, Norway, 33Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, 34Rheumatology, Queen Elizabeth Hospital, Adelaide, Australia, 35Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, 36Department of Medicine, Experimental Rheumatology Unit, Solna, Sweden, 37Department of Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, 38Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, 39Oklahoma Medical Research Foundation, Oklahoma City, OK, 40Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 41Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: genetics and sex bias, Sjogren's syndrome, X chromosome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Primary Sjögren’s syndrome (pSS) has a strong female bias of greater than 10 to 1. This difference in risk of disease between the sexes has not been explained. We hypothesize that the number of X chromosomes is important for this bias, and that examination of patients for rare X chromosome aneuploides will inform the sex bias for those with a normal chromosome complement.

Methods:

We evaluated the hypothesis of an X chromosome dose effect by analyzing the presence of 47,XXY (Klinefelter’s syndrome, 1 in 500 live male births) among a large cohort of subjects with pSS. All subjects with pSS met the American-European Consensus Classification Criteria for Sjögren’s syndrome.  The presence of extranumerary X chromosomes was determined by examination of fluorescence intensity of single nucleotide polymorphisms from the X and Y chromosomes from either Illumina genome-wide association study platform or the ImmunoChip.  Karyotype or fluorescent in situ hybridization confirmed some of these results. 

Results: Among 126 pSS men, there were 4 with 47,XXY.  This was significantly different from healthy controls (1 of 1254 had 47,XXY, p=0.0012 by Fisher’s exact test) as well as when compared to men with rheumatoid arthritis and the expected population frequency, but not different from published results in men with systemic lupus erythematosus (SLE).  Using Bayes’ theorem along with the population prevalence of Sjögren’s and Klinefelter’s syndromes as well as the finding of ~1 in 30 Sjögren’s men with 47,XXY, we calculate that men with Klinefelter’s syndrome have a risk of pSS about equal to that of women.

Conclusion: Combined with our previous data that 3 of 1,033 SS women, but only in two of the 7,074 female controls, have 47,XXX, which is found in 1 in 1000 live female births (p=0.02, OR=10.29, 95% CI: 1.18-123.47), these results are consistent with the hypothesis that the number of X chromosomes is important for the sex bias of pSS.


Disclosure: V. M. Harris, None; J. Cavett, None; B. Kurien, None; K. Liu, None; K. A. Koelsch, None; L. Radfar, None; D. M. Lewis, None; D. U. Stone, None; S. Li, None; B. Segal, None; D. J. Wallace, None; M. H. Weisman, None; J. A. Kelly, None; M. Alarcon-Riquelme, None; B. Pons-Estel, None; R. Jonsson, None; X. Lu, None; J. Gottenberg, None; J. M. Anaya, None; D. S. Cunninghame-Graham, None; E. C. Keystone, Janssen Inc., 2,Abbott/AbbVie, 5,Amgen, 2,Bristol-Myers Squibb, 5,Janssen Inc., 5,Hoffmann-La Roche, Inc., 5,Janssen Inc., 2,Janssen Inc., 5,Merck Pharmaceuticals, 5,Merck Pharmaceuticals, 5,Pfizer Pharmaceuticals, 5,Pfizer Pharmaceuticals, 5; A. J. W. Huang, None; M. T. Brennan, None; P. Hughes, None; G. Illei, AstraZeneca, 1,MedImmune, 3; C. Miceli, None; V. Bykerk, None; G. Hirschfield, None; G. Xie, None; W. F. Ng, None; G. Nordmark, None; P. Eriksson, None; R. Omdal, None; N. L. Rhodus, None; M. Rischmueller, None; M. D. Rohrer, None; M. Wahren-Herlenius, None; T. Witte, None; X. Mariette, Biogen Idec, 2,Pfizer Inc, 2,Bristol-Myers Squibb, 5,Pfizer Inc, 5,AstraZeneca, 5,GlaxoSmithKline, 5; C. Lessard, None; J. B. Harley, None; K. L. Sivils, Lilly, 2; R. H. Scofield, Lilly, UCB, 5.

To cite this abstract in AMA style:

Harris VM, Cavett J, Kurien B, Liu K, Koelsch KA, Radfar L, Lewis DM, Stone DU, Li S, Segal B, Wallace DJ, Weisman MH, Kelly JA, Alarcon-Riquelme M, Pons-Estel B, Jonsson R, Lu X, Gottenberg J, Anaya JM, Cunninghame-Graham DS, Keystone EC, Huang AJW, Brennan MT, Hughes P, Illei G, Miceli C, Bykerk V, Hirschfield G, Xie G, Ng WF, Nordmark G, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer MD, Wahren-Herlenius M, Witte T, Mariette X, Lessard C, Harley JB, Sivils KL, Scofield RH. Klinefelter’s Syndrome (47,XXY) Among Men with Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/klinefelters-syndrome-47xxy-among-men-with-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/klinefelters-syndrome-47xxy-among-men-with-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology